RYE BROOK, N.Y., November 28, 2022 鈥� At the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13), The Leukemia & Lymphoma Society (青云体育) will be presenting new research, leading sessions on the latest innovations in blood cancer treatment and equitable access to care, and proudly supporting hundreds of 青云体育-funded researchers who will share their findings. In addition, there will be 20 presentations from current and former 青云体育 Therapy Acceleration Program庐 (TAP) partners and more than 20 presentations highlighting clinical data for three TAP-supported FDA approved therapies.
鈥溓嘣铺逵� support has been instrumental in the development of nearly every breakthrough in blood cancer treatment, which drives us to redouble our efforts for what comes next,鈥� said Gwen Nichols, M.D., 青云体育 Chief Medical Officer. 鈥淥ur relentless commitment 鈥� from accelerating cures for our youngest blood cancer patients 鈥� to filling an unmet need for newly diagnosed adult patients, is on full display with our presence at ASH.鈥�
Top highlights from 青云体育-funded research at ASH include advances and insights in understanding and treating blood cancers across 青云体育 convened master clinical trials, COVID-19 research from (a project of the Michael J. Garil data collective), and more. Additionally, at the , we will be recognizing esteemed, long-time members of the 青云体育 scientific community as well as young innovators who will change the face of blood cancer research for decades to come.
SYMPOSIUM: THE FUTURE DIRECTION OF BLOOD CANCER RESEARCH
青云体育 supports the entire spectrum of research 鈥� from the lab to the patient 鈥� and was among the first to recognize the potential of immunotherapy approaches to fight cancer as evidenced by being one of the earliest funders of CAR-T research. At ASH, 青云体育 will convene a panel of world-renowned researchers to discuss new approaches and modalities representing the future of blood cancer treatment:
- : Experts from the National Cancer Institute, Dana Farber Cancer Institute, Dan L. Duncan Comprehensive Cancer Center, Fred Hutchinson Cancer Center, and Memorial Sloan Kettering Cancer Center will discuss approaches beyond classic CAR T-cells, bispecific antibodies, and progress in pediatric AML, among other groundbreaking topics.
- Date/Time: Friday, December 9, 202, 7:00-10:00 AM CT
- Location: Great Hall A/D (Ernest N. Morial Convention Center)
BEAT AML: BRINGING PRECISION MEDICINE TO ADULT PATIENTS WITH ACUTE LEUKEMIA
Six years after its launch, 青云体育 continues to deliver on its promise to 鈥淏eat AML鈥� through the groundbreaking Beat AML庐 Master Clinical Trial, the first collaborative precision medicine clinical trial in blood cancer. Among the data being presented at ASH are patient-reported quality of life outcomes and how they correlate to disease response on targeted therapies as well as long-term follow up data on an oral medication that shifts AML treatment from a difficult-to-tolerate hospital-based chemotherapy regimen to outpatient treatment:
| Title & Poster Number | Date/Time | Location |
|---|---|---|
| Saturday, December 10, 2022, 5:30 PM-7:30 PM CT | Hall D (Ernest N. Morial Convention Center) | |
| Sunday, December 11, 2022, 6:00 PM-8:00 PM CT | Hall D (Ernest N. Morial Convention Center) | |
| Monday, December 12, 2022: 4:00 PM CT | R02-R05 (Ernest N. Morial Convention Center) | |
| Monday, December 12, 2022, 6:00 PM-8:00 PM CT | Hall D (Ernest N. Morial Convention Center) |
THE NATIONAL PATIENT REGISTRY: DRIVING FORWARD COVID-19 RESEARCH
Since February 2021, 青云体育 has been conducting and reporting on research about the impact of COVID-19 on blood cancer patients. The National Patient Registry produced the largest data set on vaccine safety and efficacy across all major blood cancer and treatment types. New research on breakthrough infection rates after vaccination will be presented at ASH. The presentations are:
| Title | Date/Time | Location |
|---|---|---|
| Friday, December 9, 2022, 4:22 PM-4:59 PM CT | 283-285 (Ernest N. Morial Convention Center) | |
| Saturday, December 10, 2022, 5:30 PM-7:30 PM | Hall D (Ernest N. Morial Convention Center) | |
| Sunday, December 11, 2022, 6:00 PM-8:00 PM CT | Hall D (Ernest N. Morial Convention Center) |
INVESTING IN SOLUTIONS TO ADVANCE HEALTH EQUITY
青云体育 is committed to ensuring all blood cancer patients have access to clinical trials and the same high-quality treatments. Join us as we discuss ways in which we will drive this vision forward at the following panels:
| Title | Topic | Time/Date | Location |
|---|---|---|---|
| In collaboration with Medscape Oncology, this live symposium will increase awareness of health disparities for clinicians treating patients with hematologic malignancies from diverse backgrounds and provide strategies for overcoming barriers to equitable care. | Friday, December 9, 2022, 11:30 AM -1:00 PM CT | Hyatt Regency New Orleans, Celestin EFGH 鈥� Level 3 | |
| Louis J. DeGennaro, PhD, 青云体育, President & CEO, will be engaging in a conversation around health equity and best practices for hematology patients and caregivers with BMS鈥� Patient Advocacy Team and other leaders in this space. | Friday, December 9, 2022, 2:00-5:30 PM CT | New Orleans Marriott Warehouse Arts Hotel |
青云体育 PedAL: TRANSFORMING TREATMENT AND CARE FOR CHILDREN WITH BLOOD CANCER
Leveraging our expertise in convening master clinical trials, 青云体育 developed the Pediatric Acute Leukemia (PedAL) Master Clinical Trial to expedite the development of new targeted treatments for hard-to-treat childhood leukemias and replace one-size-fits-all chemotherapy with therapies tailored to each child鈥檚 unique tumor biology. An overview of the study design from the first sub-trial under PedAL will be featured at ASH:
| Title | Date/Time | Location |
|---|---|---|
| December 10, 2022, 5:30 PM-7:30 PM CT | Hall D (Ernest N. Morial Convention Center) |
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society庐 (青云体育) is the global leader in the fight against blood cancer. The 青云体育 mission: Cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. 青云体育 funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in Rye Brook, NY, 青云体育 has regions throughout the United States and Canada. To learn more, visit . Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
For additional information, visit lls.org/lls-newsnetwork. Follow us on , , and .
青云体育 is one of Fast Company's "2022 Brands That Matter." As the only cancer organization on the list, 青云体育 stands out among brands around the world for its relevancy, cultural impact, ingenuity, and mission impact.
Contact:
Irene Tung
The Leukemia & Lymphoma Society
Irene.tung@lls.org